Moderna has announce that their approved COVID-19 admirer vaccine and prospect relay transmitter that centre on variate of concern are show promising resultant role in preliminary information . The vaccinum boosters being investigated were delivered in the standard approved dosage of 50 micrograms and in a 100 microgram version .
Data release comes from 120 participants , receive the received vaccinum and two new interpretation in the same dosage quantity . The company report that the standard booster create a 37 - fold increase in neutralise antibodies against omicron . The higher Venus’s curse termination in antibody levels approximately 83 - fold higher than pre - boost level . The new versions produce equally mellow results at either dose .
“ The dramatic step-up in COVID-19 cases from the Omicron variant is pertain to all . However , these data showing that the currently authorized Moderna COVID-19 booster can boost neutralizing antibody levels 37 - fold high than pre - boost levels are assure , ” Stéphane Bancel , Chief Executive Officer of Moderna , said in astatement .
“ To respond to this extremely transmitted variant , Moderna will continue to rapidly set ahead an Omicron - specific booster candidate into clinical testing in case it becomes necessary in the time to come . We will also bear on to generate and share information across our booster unit strategy with public health authorities to help them make grounds - based decision on the best vaccination strategies against SARS - CoV-2 . ”
The company continues to investigate the variant - specific boosters which are being evaluated in an ongoing Phase 2/3 test of approximately 300 - 600 player per arm . Moderna reports that 305 received the 100 microgram version of the booster and that was generally well tolerated .
The Omicron variant is believe to pose a reinfection risk5.4 times highercompared to the Delta variant , so vaccines and boosters are primal weapons to fight it off .
